Literature DB >> 22170556

Characterization of neutralizing antibodies in adults after intranasal vaccination with an inactivated influenza vaccine.

Akira Ainai1, Shin-Ichi Tamura, Tadaki Suzuki, Ryo Ito, Hideki Asanuma, Takeshi Tanimoto, Yasuyuki Gomi, Sadao Manabe, Toyokazu Ishikawa, Yoshinobu Okuno, Takato Odagiri, Masato Tashiro, Tetsutaro Sata, Takeshi Kurata, Hideki Hasegawa.   

Abstract

The levels and properties of neutralizing antibodies in nasal wash and serum collected from five healthy adults were examined after intranasal administration of an A/Uruguay/716/2007 (H3N2) split vaccine (45 µg hemagglutinin (HA) per dose; five doses, with an interval of 3 weeks between each dose). Prior to the assays, nasal wash samples were concentrated so that the total amount of antibodies was equivalent to about 1/10 of that found in the natural nasal mucus. Vaccination induced virus-specific neutralizing antibody responses, which increased with the number of vaccine doses given. Neutralizing antibodies were produced more efficiently in the nasal passages than in the serum: A ≥4-fold increase in nasal neutralization titres was observed after the second vaccination in four out of five subjects, whereas a rise in serum neutralization titres was observed only after the fifth vaccination. Nasal and serum neutralizing antibodies were mainly found in the polymeric IgA and monomeric IgG fractions, respectively, after gel filtration. Taken together, these results suggest that intranasal administration of an inactivated split vaccine induces high levels of nasal neutralizing antibodies (primarily polymeric IgA) and low levels of serum neutralizing antibodies (primarily monomeric IgG).
Copyright © 2011 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22170556     DOI: 10.1002/jmv.22273

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  5 in total

1.  Cytokine production in whole-blood cultures following immunization with an influenza vaccine.

Authors:  Tetsuo Nakayama; Takuji Kumagai; Yasuyo Kashiwagi; Hironori Yoshii; Kenta Honjo; Ritsuko Kubota-Koketsu; Yoshinobu Okuno; Shigeru Suga
Journal:  Hum Vaccin Immunother       Date:  2018-08-28       Impact factor: 3.452

2.  Methylglycol chitosan and a synthetic TLR4 agonist enhance immune responses to influenza vaccine administered sublingually.

Authors:  Justin L Spinner; Hardeep S Oberoi; Yvonne M Yorgensen; Danielle S Poirier; David J Burkhart; Martin Plante; Jay T Evans
Journal:  Vaccine       Date:  2015-09-21       Impact factor: 3.641

3.  Relationship of the quaternary structure of human secretory IgA to neutralization of influenza virus.

Authors:  Tadaki Suzuki; Akira Kawaguchi; Akira Ainai; Shin-ichi Tamura; Ryo Ito; Pretty Multihartina; Vivi Setiawaty; Krisna Nur Andriana Pangesti; Takato Odagiri; Masato Tashiro; Hideki Hasegawa
Journal:  Proc Natl Acad Sci U S A       Date:  2015-06-08       Impact factor: 11.205

4.  Secretory IgA in Mucosa of Pharynx and Larynx Plays an Important Role against Influenza A Virus Infection in Kidney Yang Deficiency Syndrome Model.

Authors:  Shaozhe Zhao; Lei Yuan; Yi Li; Longchan Liu; Zixin Luo; Qingtao Lv; Rong Rong; Yong Yang
Journal:  Evid Based Complement Alternat Med       Date:  2020-03-29       Impact factor: 2.629

5.  Intranasal vaccination with an inactivated whole influenza virus vaccine induces strong antibody responses in serum and nasal mucus of healthy adults.

Authors:  Akira Ainai; Shin-Ichi Tamura; Tadaki Suzuki; Elly van Riet; Ryo Ito; Takato Odagiri; Masato Tashiro; Takeshi Kurata; Hideki Hasegawa
Journal:  Hum Vaccin Immunother       Date:  2013-06-27       Impact factor: 3.452

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.